

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number
WO 03/030926 A1

(51) International Patent Classification⁷: A61K 38/06,
47/18, 7/00

(21) International Application Number: PCT/US02/32015

(22) International Filing Date: 4 October 2002 (04.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/327,371 5 October 2001 (05.10.2001) US

(71) Applicant (*for all designated States except US*): PRO-
CYTE CORPORATION [US/US]; 8511 - 154th Avenue
Northeast, Redmond, WA 98052-3557 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): PATT, Leonard, M.
[US/US]; 12016 - 40th Avenue Northeast, Seattle, WA
98125 (US).

(74) Agents: MESHER, James, A. et al.; Seed Intellectual
Property Law Group PLLC, Suite 6300, 701 Fifth Avenue,
Seattle, WA 98104-7092 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABLE SOLUTIONS OF PEPTIDE COPPER COMPLEXES AND COSMETIC AND PHARMACEUTICAL FORMULATIONS PRODUCED THEREFROM

(57) Abstract: Compositions are formed by adding at least one amino acid to an aqueous solution of at least one peptide copper complex, and disclosed methods impart to solutions of peptide copper complexes, chemical stability and resistance to precipitation of the complexes through the addition of at least one of certain amino acids thereto. Also disclosed are compositions comprising at least one peptide copper complex and at least one of certain amino acids, as well as compositions further comprising one or more preservatives to provide thereto resistance to microbial attack and toxicity to microbes. Medical devices, pharmaceuticals and cosmetics comprising such compositions are also disclosed.

WO 03/030926 A1

STABLE SOLUTIONS OF PEPTIDE COPPER COMPLEXES AND COSMETIC AND PHARMACEUTICAL FORMULATIONS PRODUCED THEREFROM

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Patent
5 Application No. 60/327,371 filed October 5, 2001, which application is
incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates to aqueous solutions of peptide
copper complexes, and to pharmaceutical and cosmetic preparations, as well
as medical devices, comprising such solutions.

Description of the Related Art

15 Copper is known to have many beneficial biological applications,
including, as a few examples, stimulating the accumulation of collagen and
elastin, increasing the rate of wound healing, and increasing the amount of
collagen in skin (see, e.g., Maquart, F. X., Pickart, L., Laurent, M., Gillery, P.,
Monboisse, J. C., Borel, J. P., "Stimulation of Collagen Synthesis in Fibroblast
20 Cultures by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-
Copper(2+)," *FEBS Lett.* 238(2): 343-346, 1988; Wegrowski, Y., Maquart, F. X.
and Borel, J. P., "Stimulation of Sulfated Glycosaminoglycan Synthesis by the
Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Copper(2+)," *Life*
Sciences 51: 1049-1056, 1992; Maguart, F. X., Bellon, G., Chaqour, B.,
25 Wegrowski, J., Patt L. M., Trachy, R. E., Monboisse, J. C., Chastang, F.,
Birembaut, P., Gillery, P. and Borel, J. P., "In Vivo Stimulation of Connective
Tissue Accumulation by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-
Lysine-Copper(2+) in Rat Experimental Wounds," *J. Clin. Invest.* 92: 2368-
2376, 1993).

Copper salts alone are ineffective, or even inhibitory, for such applications. The copper must be delivered in a biologically acceptable form. As an example, when copper is complexed with a biologically acceptable carrier molecule, such as a peptide, it may then be effectively delivered to cells.

5 More specifically, peptide copper complexes may be effective in this regard. Peptide copper complexes that are useful for wound healing and skin health are disclosed in U.S. Patent Nos. 4,760,051; 4,665,054; 4,877,770; 5,135,913 and 5,348,943. Peptide copper complexes, beneficial for stimulating hair growth and preventing hair loss, are disclosed in U.S. Patent Nos.
10 5,177,061; 5,214,032; 5,120,831; 5,550,183 and 5,538,945. Another beneficial application of peptide copper complexes is the prevention and healing of gastric ulcers, as disclosed in U.S. Patent Nos. 5,145,838; 4,767,753 and 5,023,237. Yet another utility of such complexes is the healing of bone, as disclosed in U.S. Patent No. 5,059,588.

15 While a number of peptide copper complexes have been identified and described as having biologically beneficial utility, there remains a need in the art for such solutions that can be more effectively, economically and easily used, alone or as a component of pharmaceuticals, medical devices, or cosmetic products. More specifically in this regard, needed in the art are
20 solutions of peptide copper complexes that are chemically stable, that maintain the complexes in solution, even at higher concentrations and lower temperatures, and that resist microbial growth. Also needed in the art are pharmaceuticals, medical devices, or cosmetic products that comprise such solutions of peptide copper complexes. The present invention fulfills these
25 needs and provides further related advantages.

BRIEF SUMMARY OF THE INVENTION

In one embodiment, the present invention provides compositions formed from adding at least one amino acid to an aqueous solution of at least one peptide copper complex, with the proviso that the amino acid is not
30 histidine. It has been surprisingly found that such compositions, by virtue of the

addition of the at least one amino acid, are characterized by the peptide copper complex having an enhanced tendency to remain solubilized despite being present at relatively high concentrations in a solution maintained at lower temperatures. It has also been surprisingly found that such compositions are
5 further characterized by exhibiting chemical stability, also by virtue of addition of the at least one amino acid.

In another embodiment, there is disclosed adding a preservative to the above composition to impart thereto greater resistance to microbial attack, as well as toxicity to microbes. Surprisingly, it has been found that
10 compositions of the present invention are resistant to microbial attack and are toxic to microbes without the addition of a preservative, where the peptide copper complex is present in solution at a sufficiently high concentration.

Other embodiments are directed to compositions that comprise an aqueous solution of at least one peptide copper complex and at least one
15 amino acid, with the proviso that the amino acid is not histidine. Yet additional embodiments are directed to such compositions that further comprise a ternary complex, the latter formed from the reaction of the peptide copper complex and the amino acid.

The present invention is also directed to a method for enhancing
20 the chemical stability of compositions that contain an aqueous solution of a peptide copper complex, by adding at least one amino acid to the solution. Also disclosed is a method to enhance the ability of peptide copper complexes to remain in solution, despite being present at a relatively high concentration in an aqueous solution maintained at a relatively low temperature or frozen and
25 then thawed, by adding at least one amino acid to the aqueous solution of the at least one peptide copper complex.

Finally, in another embodiment, the present invention is also directed to a medical device that comprises a disclosed composition.

These and other aspects of the present invention will be evident
30 upon reference to the following detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, in one embodiment, disclosed is a composition formed by adding at least one amino acid to an aqueous solution of at least one peptide copper complex, with the proviso that the amino acid is not histidine. In certain specific embodiments, the at least one amino acid is glycine, lysine, arginine or a mixture thereof. Also, in certain other specific embodiments, the at least one peptide copper complex is glycyl-histidyl-lysine:copper(II) ("GHK-Cu"), valyl-histidyl-lysine:copper(II) ("VHK-Cu") or alanyl-histidyl-lysine:copper(II) ("AHK-Cu"). Such peptides may be in either the L or D form.


10 In a related, more specific embodiment, they are all in the L form.

As used herein, the term "peptide copper complex" refers to a coordination compound comprising a peptide molecule and a copper ion non-covalently complexed therewith. The peptide molecule serves as the complexing agent by donating electrons to the copper ion to yield the non-covalent complex. The peptide molecule is a chain of two or more amino acid units covalently bonded together via amide linkages (for example, -CONH-), the formation of such linkages being accompanied by the elimination of water. The amino acid units are from amino acids that are naturally occurring or otherwise. Also, at least one amide linkage nitrogen atom may have covalently bonded thereto either a hydrogen atom or another moiety.


15 20

Generally, an amino acid consists of an amino group, a carboxyl group, a hydrogen atom, and an amino acid side-chain moiety – all bonded, in the case of an alpha-amino acid, to a single carbon atom that is referred to as an alpha-carbon. The amino acid units of the peptide copper complexes comprised in the compositions of the present invention may be provided by amino acids other than alpha-amino acids. For example, the amino acids may be beta- or gamma-amino acids, such as those shown below.


25



alpha-amino acid



beta-amino acid







gamma-amino acid

where X is the amino acid side-chain moiety.

- 5 Naturally occurring amino acids, that is, amino acids from which the amino acid units of naturally occurring proteins are derived, and their respective naturally occurring, amino acid side chain moieties, are shown below in Table 1. These naturally occurring amino acids are all in the L configuration, referring to the optical orientation of the alpha carbon or other carbon atom
- 10 bearing the amino acid side chain. A peptide molecule may also comprise amino acids that are in the D optical configuration.

Table 1

NATURALLY OCCURRING AMINO ACID SIDE-CHAIN MOETIES

Amino Acid Side Chain Moiety	Amino Acid
$-\text{H}$	Glycine
$-\text{CH}_3$	Alanine
$-\text{CH}(\text{CH}_3)_2$	Valine
$-\text{CH}_2\text{CH}(\text{CH}_3)_2$	Leucine
$-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$	Isoleucine
$-(\text{CH}_2)_4\text{NH}_3^+$	Lysine
$-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)\text{NH}_2^+$	Arginine
$-\text{CH}_2-$ 	Histidine
$-\text{CH}_2\text{COO}-$	Aspartic Acid
$-\text{CH}_2\text{CH}_2\text{COO}-$	Glutamic Acid
$-\text{CH}_2\text{CONH}_2$	Asparagine
$-\text{CH}_2\text{CH}_2\text{CONH}_2$	Glutamine
$-\text{CH}_2-$ 	Phenylalanine
$-\text{CH}_2-$ 	Tyrosine
$-\text{CH}_2-$ 	Tryptophan
$-\text{CH}_2\text{SH}$	Cysteine
$-\text{CH}_2\text{CH}_2\text{SCH}_3$	Methionine
$-\text{CH}_2\text{OH}$	Serine
$-\text{CH}(\text{OH})\text{CH}_3$	Threonine

One example of a copper peptide complex is alanyl-histidyl-lysine:copper(II). Copper(II), as is well understood by the skilled artisan, designates a copper ion having a valence of 2 (e.g., Cu^{+2}). Additional examples of peptide copper complexes, at least some of which are encompassed in
5 embodiments of the present invention, include, but are not limited to, those described in U.S. Patent Nos. 4,665,054; 4,760,051; 4,767,753; 4,877,770; 5,023,237; 5,059,588; 5,120,831; 5,135,913; 5,145,838; 5,177,061; 5,214,032; 5,348,943; 5,538,945 and 5,550,183.

Further, the expression "peptide copper complex," as used herein,
10 encompasses peptide copper complex derivatives. The expression "peptide copper complex derivative," as used herein, refers to a peptide copper complex where the peptide molecule thereof has: 1) at least one amino acid side chain moiety that is a modification and/or variation of a naturally occurring, amino acid side-chain moiety; and/or 2) at least one of the hydrogens, bonded to an amide
15 linkage nitrogen atom, substituted with a different moiety; and/or 3) the carboxyl group of the carboxyl terminal residue esterified or otherwise modified; and/or 4) at least one hydrogen, bonded to the nitrogen atom of the amino-terminal residue, substituted with a different moiety.

The amino acid side-chain moieties of the peptide copper
20 complex derivatives may include alkyl, aryl, arylalkyl, alkoxy, or aryloxy moieties. As used herein, "alkyl" means a straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated aliphatic hydrocarbon containing from 1 to 18 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl and the like; while saturated
25 branched alkyls include isopropyl, sec-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative, saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, -CH₂cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl, cyclohexenyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an
30 "alkenyl" or "alkynyl," respectively). Representative alkenyls include ethylenyl,

1-butenyl, isobutylenyl, 2-methyl-2-butenyl, and the like; while representative alkynyls include acetylenyl, 2-butyne, 3-methyl-1-butyne, and the like.

Also, as used herein, "aryl" means an aromatic carbocyclic moiety such as phenyl or naphthyl, and may be substituted or unsubstituted.

5 "Arylalkyl," as used herein, means an alkyl having at least one alkyl hydrogen atom replaced with a substituted or unsubstituted aryl moiety, such as benzyl (*i.e.*, -CH₂phenyl, -(CH₂)₂phenyl, -(CH₂)₃phenyl, -CH(phenyl)₂, and the like). As some examples, the amino acid side-chain moieties of alanine, valine, leucine, isoleucine and phenylalanine may generally be classified as alkyl, aryl or
10 arylalkyl moieties.

"Alkoxy" and "aryloxy," as used herein, refer, respectively, to alkyl and aryl moieties, as defined above, but each further comprising an oxygen atom used to link the moiety to the amino acid.

Additionally, the peptide copper complex derivative may, for
15 example, be N-alkylated at one or more peptide bonds; and/or its carboxyl terminus may be esterified, for example, with a methyl, ethyl, or benzyl group, or may be reduced to a hydroxy or aldehyde. Additionally, the peptide copper complex derivative may, for example, be N-alkylated, N-acylated or N-sulfonylated at the amino terminus with, for example, methyl, benzyl, acetyl,
20 benzoyl, methanesulfonyl, or fluorenyloxycarbonyl moieties.

Examples of the peptide copper complex derivatives, encompassed in embodiments of the present invention, include, but are not limited to, those disclosed and described in the above-cited U.S. Patents that are directed to peptide copper complexes, as well as those disclosed and
25 described in the published PCT application having the international publication number WO 94/03482.

As one specific example, a disclosed composition may comprise a peptide copper complex derivative that is a derivative of GHK-Cu having the general formula:

30 [glycyl-histidyl-lysine-R] : copper(II)

where R is an alkyl moiety containing from 1 to 18 carbon atoms, an aryl moiety containing from 6 to 12 carbon atoms, an arylalkyl moiety, an alkoxy moiety containing from 1 to 12 carbon atoms, or an aryloxy moiety containing from 6 to 12 carbon atoms. This derivative of GHK-Cu is further described in the above-cited U.S. Patents that are directed to peptide copper complexes.

The above compositions may be prepared from aqueous solutions of peptide copper complexes. Such solutions are prepared by methods that are well known to those skilled in the art. For example, an amount of dried peptide copper complex suitable for a desired concentration is readily dissolved in water with mixing and gentle heating. An alternative method is to prepare a solution of the desired peptide, followed by the addition of a copper salt in the desired molar ratio to yield the desired solution of the peptide copper complex. Examples of copper salts that may be used are cupric chloride and cupric acetate. When aqueous solutions of peptide copper complexes are prepared, the solutions are neutralized, typically with NaOH.

The molar ratio of the at least one peptide copper complex to the at least one amino acid, for embodiments directed to the above-disclosed compositions, ranges from 1:1 to 3:1. In one specific embodiment, the molar ratio is about 1:1. In various embodiments, the concentration of the at least one peptide copper complex, by weight of solution, is in the range of about 1% to about 25%, about 5% to about 15%, and about 7% to about 10%, respectively. Also, in some embodiments, the pH of the solution of the at least one peptide copper complex is adjusted by adding an acid. Typically, the acid used is HCl. However, other acids may be used, such as other inorganic acids, or organic acids. In certain embodiments, the adjusted pH is in the range of about 4.5 to about 7.2.

In another embodiment, at least one preservative is added to the above-disclosed, representative composition to impart resistance thereto to microbial attack and toxicity to microbes. Examples of such added preservatives include, but are not limited to, diazolidinyl urea, benzyl alcohol phenoxyethanol, imidazolidinyl urea, iodopropynyl butylcarbamate, sodium

hydroxymethyglycinate, methylparaben, propylparaben, isopropylparaben, n-butylparaben, isobutylparaben, or a mixture thereof. Other preservatives, including mixtures thereof, may be used, as is appreciated by those skilled in the art. In yet another embodiment, the composition further comprises
5 propylene glycol. The latter is used to dissolve the above parabens when they are at high concentrations.

As previously noted, it has unexpectedly been found that when the at least one peptide copper complex is present in solution at sufficiently high concentrations, the compositions of the present invention are not only
10 resistant to microbial attack, but toxic to microbes, without the addition of a preservative. This is the case when the concentration of the at least one peptide copper complex is at least 7.5% by weight of solution. Also, as previously noted, it has been surprisingly found that compositions, formed by adding at least one amino acid to an aqueous solution of at least one peptide
15 copper complex (as disclosed above), are chemically stable, by virtue of adding the at least one amino acid. As used herein, "chemical stability" refers to the ability of a composition to maintain at least 90% of its pharmaceutical or desired chemical activity for a desired period of time.

It has also been surprisingly found, as noted previously, that
20 adding at least one amino acid to an aqueous solution of at least one peptide copper complex (as disclosed above), enhances the ability of the at least one peptide copper complex to remain solubilized. As a more specific example, it has been found that, at peptide copper complex concentrations of up to at least 10% by weight of solution, the addition of glycine or lysine to the solution can
25 prevent precipitation of the at least one peptide copper complex. This has been found when the solutions are maintained at ambient temperatures (15°C to 30°C), as well as at refrigeration temperatures (2°C to 8°C) for extended periods of time (up to three weeks). This has also been found when the solutions are frozen (at -15°C to -20°C) and then thawed.

30 In another embodiment, the present invention is directed to a composition comprising an aqueous solution of at least one peptide copper

complex and at least one amino acid, with the proviso that the amino acid is not histidine. In more specific, related embodiments, the amino acid is glycine, lysine, arginine or a mixture thereof. In another related embodiment, the composition further comprises a ternary complex formed from the at least one peptide copper complex and the at least one amino acid. An example of such a ternary complex, formed when glycine is added to an aqueous solution of GHK-Cu, is:

glycyl-histidyl-lysine:copper(II):glycine

10

As can be appreciated by one skilled in the art, an active drug substance may be combined with a disclosed composition of the present invention to provide a pharmaceutical preparation. The latter would typically also comprise an inert and physiologically-acceptable carrier or diluent, such as water, physiological saline, bacteriostatic saline, a petrolatum based cream, a pharmaceutically acceptable gel, a short chain alcohol, or a short chain glycol

15

Further, a disclosed composition may be combined with a suitable agent to provide a cosmetic preparation, as would be appreciated by one skilled in the art. Such agents may include, for example, a sunscreen agent, a skin-conditioning agent, a tanning agent, a skin protectant, an emollient, a humectant, or a mixture thereof. Also, such cosmetic preparations may further include an emulsifying agent, a surfactant, a thickening agent, an excipient, or a mixture thereof, as well as other additives, including: a fatty alcohol, a fatty acid, an organic base, an inorganic base, a preserving agent, a wax ester, a steroid alcohol, a triglyceride ester, a phospholipid, a polyhydric alcohol ester, a fatty alcohol ether, a hydrophilic lanolin derivative, a hydrophilic beeswax derivative, a cocoa butter wax, a silicon oil, a pH balancer, a cellulose derivative, a hydrocarbon oil, or a mixture thereof.

20

25

Accordingly, in another embodiment, a disclosed composition is in the form of a liquid, lotion, cream, gel, emulsion, or microemulsion.

30

In another aspect, the present invention is directed to a method for imparting chemical stability to a composition comprising an aqueous solution

of at least one peptide copper complex by adding to the solution at least one amino acid. In specific related embodiments, the at least one amino acid added is glycine, lysine, arginine or a mixture thereof, and the molar ratio of the at least one peptide copper complex to the at least one amino acid is at least about 1:1.

Also disclosed is a method for preventing the precipitation of peptide copper complexes from aqueous solutions of the same by adding at least one amino acid to the solution. Specific embodiments are directed to such a method where the at least one amino acid added is glycine, lysine, arginine or a mixture thereof, and the molar ratio of the at least one peptide copper complex to the at least one amino acid is at least about 1:1. The latter disclosed methods are directed to preventing precipitation of the peptide copper complexes at ambient (15°C to 30°C) or refrigeration temperatures (2°C to 8°C), or when the solution is frozen (at -15°C to -20°C) and then thawed.

Finally, in another aspect, the present invention is directed to medical devices that comprise a disclosed composition. One example of such a device is a sterile gauze pad, impregnated with a disclosed composition in the form of a gel for application to a wound.

The following examples, which illustrate the preparation, characterization, and utility of certain embodiments of the present invention, are provided for the purpose of illustration, not limitation. For all examples, concentrations are expressed as a percentage by weight of the solution.

EXAMPLES

EXAMPLE 1

Solutions of glycyl-L-histidyl-L-lysine:copper(II) complex were prepared at a concentration of 10% with and without the addition of an amino acid. In addition, the pH of one sample was decreased to 4.5.

<u>Ingredients</u>	<u>Concentration</u>
Solution 1A:	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	10%
PH	6.7
Solution 1B:	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	10%
Glycine	1.8%
PH	6.5
Solution 1C:	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	10%
L-Lysine	5.2%
PH	6.5
Solution 1D:	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	10%
PH	4.5

After formulation, the solutions were filtered through 0.2 micron filters and stored under three conditions of temperature: ambient (room temperature), refrigerated, and frozen. After three days, the samples were
5 examined (after complete thawing in the case of the frozen samples).

Solubility Results after 3 Days			
	Room Temperature	Refrigerated	Freeze-Thaw
Solution 1A	Clear deep blue solution, no precipitate	Deep blue solution. Precipitate on bottom.	Deep blue solution. Lots of precipitate on bottom.
Solution 1B	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate	Deep blue solution. Some precipitate on bottom.
Solution 1C	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate
Solution 1D	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate	Deep blue solution. Some precipitate on bottom.

The addition of a L-lysine to the solution of peptide copper complex prevented the formation of a precipitate upon storage at refrigerated conditions or upon freezing followed by thawing. The addition of glycine also prevented formation of a precipitate upon storage at refrigerated conditions, but allowed some precipitation upon freezing followed by thawing. Lowering the pH to 4.5 also aided in the prevention of precipitate formation.

EXAMPLE 2

The solutions of Example 1 were stored for an additional 3 weeks at room temperature and at refrigerated conditions. The following results were observed.

Solubility Results after 3 Weeks		
	Room Temperature	Refrigerated
Solution 1A	Deep blue solution. Precipitate on bottom.	Deep blue solution. Lots of precipitate on bottom.
Solution 1B	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate
Solution 1C	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate
Solution 1D	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate

The addition of a L-lysine or glycine to the solution of peptide copper complex prevented the formation of a precipitate upon storage at refrigerated conditions. Lowering the pH to 4.5, instead of adding an amino acid, also aided in the prevention of precipitate formation.

5

EXAMPLE 3

The solutions of Example 1 were stored for a total of 10 weeks at room temperature and at refrigerated conditions. The following results were observed.

10

Solubility Results after 10 Weeks		
	Room Temperature	Refrigerated
Solution 1A	Deep blue solution. Lots of precipitate on bottom.	Deep blue solution. Lots of precipitate on bottom.
Solution 1B	Clear deep blue solution, no precipitate	Deep blue solution. Some precipitate on bottom.
Solution 1C	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate
Solution 1D	Clear deep blue solution, no precipitate	Deep blue solution. Some precipitate on bottom.

The addition of L-lysine to the solution of peptide copper complex prevented the formation of a precipitate upon storage at these refrigerated conditions. The addition of glycine resulted in a reduced amount of precipitation upon storage at these refrigerated conditions, as did lowering the pH to 4.5.

15

EXAMPLE 4

Solutions of glycyl-L-histidyl-L-lysine:copper(II) complex were prepared at a concentration of 8% with and without the addition of an amino acid or selected preservatives.

20

<u>Ingredients</u>	<u>Concentration</u>
Solution 4A	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	8%
Imidazolidinyl Urea	0.3%
Methylparaben	0.1%
Propylparaben	0.03%
PH	6.4

Solution 4B	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	8%
Diazolidinyl Urea	0.3%
Methylparaben	0.11%
Propylparaben	0.03%
Propylene Glycol	0.56%
PH	6.3

<u>Ingredients</u>	<u>Concentration</u>
Solution 4C	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	8%
PH	6.5

Solution 4D	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	8%
PH	5.0

Solution 4E	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	8%
Glycine	1.6%
Diazolidinyl Urea	0.3%
Methylparaben	0.11%
Propylparaben	0.03%
Propylene Glycol	0.56%
PH	6.4

After formulation the solutions were filtered through 0.2 micron filters and were tested for their ability to inhibit microbial growth. Testing was performed by standard methods as described in the current USP <51>. The microorganisms tested included *Canada ablicans* (*C. albicans*), *Aspergillus niger* (*A. niger*), *Escherichia coli* (*E. coli*), *Pseudomonas aeruginosa* (*P. aeruginosa*), and *Staphylococcus aureus* (*S. aureus*). Testing of the samples gave the following results, shown as Examples 4a through 4e. In all cases, the concentrated solutions of peptide copper complex, with or without addition of preservatives, inhibited microbial growth or were toxic to microbial growth.

Example 4a Inhibition of Microbial Growth by Solution 4A					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	170,000	490,000	600,000	440,000	500,000
Day 14	LT 100	LT 100	LT 100	LT 100	LT 100
Day 28	LT 100	LT 100	LT 100	LT 100	LT 100
LT = Less Than					

10

Example 4b Inhibition of Microbial Growth by Solution 4B					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	170,000	490,000	600,000	440,000	500,000
Day 14	LT 100	LT 100	LT 100	LT 100	LT 100
Day 28	LT 100	LT 100	LT 100	LT 100	LT 100
LT = Less Than					

Example 4c Inhibition of Microbial Growth by Solution 4C					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	170,000	490,000	600,000	440,000	500,000
Day 14	57,000	58,000	LT 100	LT 100	LT 100
Day 28	57,000	LT 100	LT 100	LT 100	LT 100
LT = Less Than					

Example 4d Inhibition of Microbial Growth by Solution 4D					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	170,000	490,000	600,000	440,000	500,000
Day 14	LT 100	100,000	LT 100	LT 100	LT 100
Day 28	LT 100	200	LT 100	LT 100	LT 100
LT = Less Than					

Example 4e Inhibition of Microbial Growth by Solution 4E					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	170,000	490,000	600,000	440,000	500,000
Day 14	LT 100	LT 100	LT 100	LT 100	LT 100
Day 28	LT 100	LT 100	LT 100	LT 100	LT 100
LT = Less Than					

EXAMPLE 5

- Two solutions of glycyl-L-histidyl-L-lysine:copper(II) complex were prepared having a peptide copper complex concentration of 7.5% and an added L-arginine concentration of 3%. Selected preservatives were also added to one of the solutions.

<u>Ingredients</u>	<u>Concentration</u>
Solution 5A	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	7.5%
L-Arginine	3.0%
PH	6.3
Solution 5B	
Purified Water	q.s. 100%
Glycyl-L-Histidyl-L-Lysine:Copper(II) complex	7.5%
L-Arginine	3.0%
Diazolidinyl Urea	0.3%
Methylparaben	0.11%
Propylparaben	0.03%
Propylene Glycol	0.56%
PH	6.3

After formulation, the solutions were filtered through 0.2 micron filters and stored under three conditions of temperature: ambient (room temperature), refrigerated, and frozen. After 48 hours, the samples were examined (after complete thawing in the case of the frozen samples).

Solubility Results after 48 hours			
Solution	Room Temperature	Refrigerated	Freeze-Thaw
5A	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate	Clear deep blue solution with precipitate on bottom
5B	Clear deep blue solution, no precipitate	Clear deep blue solution, no precipitate	Clear deep blue solution with precipitate on bottom

The addition of L-arginine to the solution of peptide copper complex prevented the formation of a precipitate upon storage at refrigerated conditions, but not upon freezing followed by thawing.

EXAMPLE 6

Solutions 5A and 5B of Example 5 were tested for their ability to inhibit microbial growth. Testing of the sample gave the following results. Both solutions inhibited microbial growth.

Example 6a					
Inhibition of Microbial Growth by Solution 5A					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	230,000	420,000	700,000	650,000	800,000
Day 14	53,000	140,000	LT 100	LT 100	1,100
Day 28	44,000	120,000	LT 100	LT 100	LT 100
LT = Less Than					

Example 6b Inhibition of Microbial Growth by Solution 5B					
	<i>A. niger</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Day 0	200,000	480,000	480,000	450,000	450,000
Day 14	200	LT 100	LT 100	LT 100	LT 100
Day 28	150	LT 100	LT 100	LT 100	LT 100
LT = Less Than					

All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

1. A composition formed by adding an amino acid to an aqueous solution of a peptide copper complex, with the proviso that the amino acid is not histidine.
2. The composition of claim 1 wherein the molar ratio of the peptide copper complex to the amino acid ranges from about 1:1 to about 3:1.
3. The composition of claim 1 wherein the molar ratio of the peptide copper complex to the amino acid is about 1:1.
4. The composition of claim 1 wherein the concentration of the peptide copper complex ranges from about 1% to about 25% by weight of the solution.
5. The composition of claim 1 wherein the concentration of the peptide copper complex ranges from about 5% to about 15 % by weight of the solution.
6. The composition of claim 1 wherein the concentration of the peptide copper complex ranges from about 7 % to about 10% by weight of the solution.
7. The composition of claim 1 wherein the pH of the solution is adjusted to from about 4.5 to about 7.2.
8. The composition of claim 1 wherein the solution comprises a preservative.

9. The composition of claim 8 wherein the preservative is diazolidinyl urea, benzyl alcohol, phenoxyethanol, imidazolidinyl urea, iodopropynyl butylcarbamate, sodium hydroxymethylglycinate, methylparaben, propylparaben, isopropylparaben, n-butylparaben, isobutylparaben, or a mixture thereof.

10. The composition of claim 9 wherein the solution further comprises propylene glycol.

11. The composition of claim 1 wherein the peptide copper complex is glycyl-L-histidyl-L-lysine:copper(II).

12. The composition of claim 1 wherein the peptide copper complex is L-alanyl-L-histidyl-L-lysine:copper(II).

13. The composition of claim 1 wherein the peptide copper complex is L-valyl-L-histidyl-L-lysine:copper(II).

14. The composition of claim 1 wherein the amino acid is glycine, lysine, arginine, or a mixture thereof.

15. The composition of claim 1 wherein the amino acid is glycine.

16. The composition of claim 1 wherein the amino acid is lysine.

17. The composition of claim 1 wherein the amino acid is arginine.

18. A medical device comprising the composition of claim 1.

19. The composition of claim 1 wherein the composition is in the form of a liquid, lotion, cream, gel, emulsion, or microemulsion.

20. A composition comprising at least one amino acid and an aqueous solution of at least one peptide copper complex, with the proviso that the at least one amino acid is not histidine.

21. The composition of claim 20 wherein the peptide copper complex is glycyl-L-histidyl-L-lysine:copper(II).

22. The composition of claim 20 wherein the peptide copper complex is L-valyl-L-histidyl-L-lysine:copper(II).

23. The composition of claim 20 wherein the peptide copper complex is L-alanyl-L-histidyl-L-lysine:copper(II).

24. The composition of claim 20 wherein the amino acid is glycine, lysine, arginine, or a mixture thereof.

25. The composition of claim 20 wherein the amino acid is glycine.

26. The composition of claim 20 wherein the amino acid is lysine.

27. The composition of claim 20 wherein the amino acid is arginine.

28. The composition of claim 20, further comprising a ternary complex of the at least one peptide copper complex and the at least one amino acid.

29. A medical device comprising the composition of claim 20.
30. The composition of claim 20 wherein the composition is in the form of a liquid, lotion, cream, gel, emulsion, or microemulsion
31. A method for enhancing the chemical stability of an aqueous solution of a peptide copper complex comprising the step of adding an amino acid to the solution.
32. The method of claim 31 wherein the amino acid is glycine, lysine, arginine, or a mixture thereof, and the molar ratio of the peptide copper complex to the amino acid is at least about 1:1.
33. A method for preventing the precipitation, at ambient temperatures, refrigeration temperatures, or upon thawing after freezing, of a peptide copper complex from an aqueous solution thereof, comprising the step of adding an amino acid to the solution.
34. The method of claim 33 wherein the amino acid is glycine, lysine, arginine, or a mixture thereof, and the molar ratio of the peptide copper complex to the amino acid is at least about 1:1.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 02/32015

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/06 A61K47/18 A61K7/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 118 665 A (PICKART LOREN R) 2 June 1992 (1992-06-02) column 7, paragraph 4 -column 8, paragraph 1; claims 12,13,26-28,32-34; examples 6,16 column 8, paragraph 3 - paragraph 4	1-30
X	US 5 164 367 A (PICKART LOREN R) 17 November 1992 (1992-11-17) column 6, paragraph 3 -column 9, paragraph 5	1-30
X	US 5 059 588 A (PICKART LOREN R) 22 October 1991 (1991-10-22) cited in the application column 1, paragraph 7 -column 2, paragraph 7	1-30
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family		
Date of the actual completion of the international search 23 January 2003		Date of mailing of the international search report 31/01/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Markopoulos, E

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Internationa Application No

PCT/us 02/32015

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 03482 A (SPORTOLETTI GIANCARLO ;DAL POZZO ALMA (IT); ELLEM IND FARMACEUTICA) 17 February 1994 (1994-02-17) cited in the application page 4, paragraph 1 - paragraph 3 -----	1-34

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/US 02/32015

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5118665	A	02-06-1992	AU 7254491 A	03-09-1991
			CA 2075705 A1	10-08-1991
			EP 0514460 A1	25-11-1992
			JP 5503939 T	24-06-1993
			WO 9112267 A1	22-08-1991
US 5164367	A	17-11-1992	AT 187646 T	15-01-2000
			AU 7565091 A	21-10-1991
			CA 2078347 A1	27-09-1991
			DE 69131847 D1	20-01-2000
			DE 69131847 T2	27-04-2000
			EP 0522004 A1	13-01-1993
			JP 5505808 T	26-08-1993
			WO 9114437 A2	03-10-1991
US 5059588	A	22-10-1991	AT 120203 T	15-04-1995
			AU 648520 B2	28-04-1994
			AU 6605090 A	16-05-1991
			CA 2067505 A1	14-04-1991
			DE 69018084 D1	27-04-1995
			DE 69018084 T2	27-07-1995
			DK 495877 T3	21-08-1995
			EP 0495877 A1	29-07-1992
			ES 2069750 T3	16-05-1995
			FI 921609 A	10-04-1992
			JP 5501253 T	11-03-1993
			NO 921454 A	10-06-1992
			WO 9105797 A1	02-05-1991
WO 9403482	A	17-02-1994	IT 1261646 B	28-05-1996
			AU 4703393 A	03-03-1994
			WO 9403482 A1	17-02-1994
			EP 0656009 A1	07-06-1995
			JP 7509704 T	26-10-1995